Acute myocardial infarction complicated by early onset of heart failure: Safety and feasibility of interhospital transfer for coronary angioplasty. Subanalysis of Killip II-IV patients from the PRAGUE-1 study

Journal of Interventional Cardiology

Volumn 16, Issue 3, 2003, Pages 201-208

  Bednář, František ^a   Widimský, Petr ^a   Groch, Ladislav ^a   Aschermann, Michael ^a   Želízko, Michael ^a   Krupička, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; NADROPARIN; SALICYLIC ACID DERIVATIVE; STREPTOKINASE; TICLOPIDINE;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY HOSPITAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG INFUSION; FATALITY; FEASIBILITY STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HEART REINFARCTION; HEART VENTRICLE FIBRILLATION; HOSPITAL ADMISSION; HUMAN; INTERHOSPITAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT TRANSPORT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SAFETY; STATISTICAL SIGNIFICANCE; THORAX PAIN;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT TRANSFER; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037864151     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0854.2003.8047.x     Document Type: Article

References (44)

1. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular fuction, and survival after myocardial infarction. N Engl J Med 1993;329:615-1622.
2. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistre-place and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602-1610.
3. Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
4. GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
5. Verheught FW, Meiger A, Lagrand WK, et al. Reocclusion: The flip side of coronary thrombosis. J Am Coll Cardiol 1996;27:766-773.
6. Brouwer MA, Bohcke JR, Veen G, et al. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 1995;26:1440-1444.
7. Simes RJ, Topol EJ, Holmes DR, et al., for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
8. Bode C, Smalling RW, Berg G. et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
9. Grines CL. Primary angioplasty: The strategy of choice. N Engl J Med 1996;335:1313-1315.
10. Barbagelata NA, Granger CB, Oqueli E, et al. TIMI grade 3 flow and reoclusion after intravenous thrombolytic therapy: A pooled analysis. Am Heart J 1997;133:273-282.
11. Liem AL, van't Hof AWJ, Hoorntje JCA, et al. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 1998;32:629-633.
12. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998:32:1312-1319.
13. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Circulation 1999;100:14-20.
14. Brodie BR, Grines CL, Ivanhoe R, et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final result from the Primary Angioplasty Registry. Circulation 1994;25:156-162.
15. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angiolasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
16. Ziljstra F, de Boer M, Hoorntje J, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
17. Gibbons R, Holmes D, Reeder G, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by a conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
18. GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-1628.
19. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: Incidence and mortality from a community wide perspective 1975-1988. N Engl J Med 1991;325:1117-1122.
20. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J Am Coll Cardiol 1995;26:668-674.
21. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992;20:1482-1489.
22. Himbert D, Juliard JM, Steg G, et al. Limits of reperfusion therapy for immediate cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 1994;74:492-494.
23. Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-1351.
24. Hibbard MD, Holmes DR Jr, Bailey KR, et al. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992;19:639-646.
25. Moosvi AR, Khaja F, Villanueva L, et al. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992;19:907-914.
26. Guyton RA, Arcidi JM Jr, Langford DA, et al. Emergency coronary bypass for cardiogenic shock. Circulation 1987;76(Suppl V):V22-V27.
27. Dunkman WB, Leinbach RC, Buckley MJ, et al. Clinical and hemodynamic results of intraaortic balloon pumping and surgery for cardiogenic shock. Circulation 1972:46:465-477.
28. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: Results of an international registry. Circulation 1995;91:873-881.
29. Bellinger RL, Callif RM, Mark DB, et al. Helicopter transport of patients during acute myocardial infarction. Am J Cardiol 1988;61:718-722.
30. Gore JM, Corrao RN, Goldberg RJ, et al. Feasibility and safety of emergency interhospital transport of patients during early hours of acute myocardial infarction. Arch Intern Med 1989;149:353-355.
31. Ziljistra F, van't Hof AWJ, Liem AL, et al. Transferring patients for primary angioplasty: A retrospective analysis of 104 selected high risk patients with acute myocardial infarction. Heart 1997;78:333-336.
32. Vermeer F, Werter C, vd Berg E, et al. Safety and feasibility of rescue PTCA or primary PTCA in patients with acute myocardial infarction admitted to a hospital without PTCA facilities. J Am Coll Cardiol 1997;29:390A.
33. Widimsky P, Groh L, Aschermann M, et al. Transport for primary PTCA: Results of the pilot phase of the PRAGUE Study-national multicenter randomized study on patients with acute myocardial infarction presenting to community hospitals [abstract]. Circulation 1998;98(suppl):I-771.
34. Straumann E, Yoon S, Naegeli B, et al. Hospital transfer for primary coronary angioplasty in high risk patients with acute myocardial infarction. Heart 1999;82:415-419.
35. Vermeer F, Oude Ophuis AJM, vd Berg EJ, et al. Prospective randomised comparsion between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: A safety and feasibility study. Heart 1999;82:426-431.
36. Widimsky P, Groch L, Zelizko M, et al., for the PRAGUE Study. Multicenter randomized trial comparing transport to primary angioplasty versus immediate thrombolysis versus combined strategy for patients with acute myocardial infarction presenting to a community hospital without catheterization laboratory. Eur Heart J 2000;21:823-831.
37. Killip T, Kimball J. Treatment of myocardial infarction in a coronary care unit. A two experience with 250 patients. Am J Cardiol 1967;20:457-464.
38. Zahn R, Schiele R, Schneider S, et al. Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: Can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the Maximal Individual Ttherapy in Aacute Myocardial Infarction Registry and the Myocardial Infarction Registry. J Am Coll Cardiol 2001;37:1827-1835.
39. Hochman JS, Sleeper LA, Webb JG, et al., for the SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999:341:625-634.
40. Hochman JS, Sleeper LA, Webb JG, et al. Effects of early revascularization for cardiogenic shock on 1 year mortality: The SHOCK trial results. Circulation 1999;100:I-369.
41. Carnendran L, Abboud R, Sleeper LA, et al. Trends in cardiogenic shock: Report from the SHOCK Study. Eur Heart J 2001;22:472-478.
42. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of TIMI-14 trial. Circulation 1999;99:2720-2732.
43. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
44. The GUSTO-V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO-V randomised trial. Lancet 2001;357:1905-1914.